117 related articles for article (PubMed ID: 16154721)
1. Toxicity, inflammation, and anti-human immunodeficiency virus type 1 activity following exposure to chemical moieties of C31G.
Catalone BJ; Miller SR; Ferguson ML; Malamud D; Kish-Catalone T; Thakkar NJ; Krebs FC; Howett MK; Wigdahl B
Biomed Pharmacother; 2005 Sep; 59(8):430-7. PubMed ID: 16154721
[TBL] [Abstract][Full Text] [Related]
2. Prolonged exposure to the candidate microbicide C31G differentially reduces cellular sensitivity to agent re-exposure.
Catalone BJ; Ferguson ML; Miller SR; Malamud D; Kish-Catalone T; Thakkar NJ; Krebs FC; Howett MK; Wigdahl B
Biomed Pharmacother; 2005 Sep; 59(8):460-8. PubMed ID: 16154719
[TBL] [Abstract][Full Text] [Related]
3. Comparative safety evaluation of the candidate vaginal microbicide C31G.
Catalone BJ; Kish-Catalone TM; Neely EB; Budgeon LR; Ferguson ML; Stiller C; Miller SR; Malamud D; Krebs FC; Howett MK; Wigdahl B
Antimicrob Agents Chemother; 2005 Apr; 49(4):1509-20. PubMed ID: 15793133
[TBL] [Abstract][Full Text] [Related]
4. Inactivation of human immunodeficiency virus type 1 by nonoxynol-9, C31G, or an alkyl sulfate, sodium dodecyl sulfate.
Krebs FC; Miller SR; Malamud D; Howett MK; Wigdahl B
Antiviral Res; 1999 Oct; 43(3):157-73. PubMed ID: 10551374
[TBL] [Abstract][Full Text] [Related]
5. Assessment of the anti-microbial agent C31G as a spermicide: comparison with nonoxynol-9.
Thompson KA; Malamud D; Storey BT
Contraception; 1996 May; 53(5):313-8. PubMed ID: 8724622
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers of cervicovaginal inflammation for the assessment of microbicide safety.
Cummins JE; Doncel GF
Sex Transm Dis; 2009 Mar; 36(3 Suppl):S84-91. PubMed ID: 19218890
[TBL] [Abstract][Full Text] [Related]
7. A non-antibiotic antimicrobial mixture (C31G): evaluation of the antimicrobial efficiency of C31G on vaginal cultures.
Calis S; Yulug N; Sumnu M; Ayhan A; Hincal AA
Boll Chim Farm; 1992 Oct; 131(9):335-8. PubMed ID: 1492969
[TBL] [Abstract][Full Text] [Related]
8. Clinical study of a C31G containing mouthrinse: effect on salivary microorganisms.
Corner AM; Brightman VJ; Cooper S; Yankell SL; Malamud D
J Clin Dent; 1990; 2(2):34-8. PubMed ID: 2090157
[TBL] [Abstract][Full Text] [Related]
9. Cyanovirin-N potently inhibits human immunodeficiency virus type 1 infection in cellular and cervical explant models.
Buffa V; Stieh D; Mamhood N; Hu Q; Fletcher P; Shattock RJ
J Gen Virol; 2009 Jan; 90(Pt 1):234-43. PubMed ID: 19088294
[TBL] [Abstract][Full Text] [Related]
10. Effect of suppository bases on the release properties of a potent antimicrobial agent (C31G).
Caliş S; Sumnu M; Hincal AA
Pharmazie; 1994 May; 49(5):336-9. PubMed ID: 8016179
[TBL] [Abstract][Full Text] [Related]
11. A randomized Phase I vaginal safety study of three concentrations of C31G vs. Extra Strength Gynol II.
Mauck CK; Weiner DH; Creinin MD; Barnhart KT; Callahan MM; Bax R
Contraception; 2004 Sep; 70(3):233-40. PubMed ID: 15325893
[TBL] [Abstract][Full Text] [Related]
12. Mucosal toxicity studies of a gel formulation of native pokeweed antiviral protein.
D'Cruz OJ; Waurzyniak B; Uckun FM
Toxicol Pathol; 2004; 32(2):212-21. PubMed ID: 15200159
[TBL] [Abstract][Full Text] [Related]
13. A phase I comparative postcoital testing study of three concentrations of C31G.
Mauck CK; Creinin MD; Barnhart KT; Ballagh SA; Archer DF; Callahan MM; Schmitz SW; Bax R
Contraception; 2004 Sep; 70(3):227-31. PubMed ID: 15325892
[TBL] [Abstract][Full Text] [Related]
14. Stampidine is a potential nonspermicidal broad-spectrum anti-human immunodeficiency virus microbicide.
D'Cruz OJ; Uckun FM
Fertil Steril; 2004 Mar; 81 Suppl 1():831-41. PubMed ID: 15019817
[TBL] [Abstract][Full Text] [Related]
15. Mice and rabbit models for oral and percutaneous absorption and disposition of amphoteric surfactant C31G.
Michaels EB; Hahn EC; Kenyon AJ
Am J Vet Res; 1983 Oct; 44(10):1977-83. PubMed ID: 6638657
[TBL] [Abstract][Full Text] [Related]
16. Sodium dodecyl sulfate and C31G as microbicidal alternatives to nonoxynol 9: comparative sensitivity of primary human vaginal keratinocytes.
Krebs FC; Miller SR; Catalone BJ; Welsh PA; Malamud D; Howett MK; Wigdahl B
Antimicrob Agents Chemother; 2000 Jul; 44(7):1954-60. PubMed ID: 10858360
[TBL] [Abstract][Full Text] [Related]
17. The microbicidal agent C31G inhibits Chlamydia trachomatis infectivity in vitro.
Wyrick PB; Knight ST; Gerbig DG; Raulston JE; Davis CH; Paul TR; Malamud D
Antimicrob Agents Chemother; 1997 Jun; 41(6):1335-44. PubMed ID: 9174195
[TBL] [Abstract][Full Text] [Related]
18. Mouse model of cervicovaginal toxicity and inflammation for preclinical evaluation of topical vaginal microbicides.
Catalone BJ; Kish-Catalone TM; Budgeon LR; Neely EB; Ferguson M; Krebs FC; Howett MK; Labib M; Rando R; Wigdahl B
Antimicrob Agents Chemother; 2004 May; 48(5):1837-47. PubMed ID: 15105142
[TBL] [Abstract][Full Text] [Related]
19. Vaginal and rectal topical microbicide development: safety and efficacy of 1.0% Savvy (C31G) in the pigtailed macaque.
Patton DL; Sweeney YT; Balkus JE; Hillier SL
Sex Transm Dis; 2006 Nov; 33(11):691-5. PubMed ID: 16641825
[TBL] [Abstract][Full Text] [Related]
20. C31G, a new agent for oral use with potent antimicrobial and antiadherence properties.
Corner AM; Dolan MM; Yankell SL; Malamud D
Antimicrob Agents Chemother; 1988 Mar; 32(3):350-3. PubMed ID: 3364952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
